CeriBell (CBLL) announced that its point-of-care electroencephalogram, EEG, system has received full FedRAMP High authorization from the U.S. government. This elite cybersecurity authorization is awarded to organizations that meet the government’s highest security requirements. Ceribell’s secure, cloud-based solution can now be adopted across federal healthcare systems, expanding access to rapid diagnosis of non-convulsive seizures for U.S. veterans and other high-risk patients. As of April 28, 2025, only 51 companies in the U.S. have achieved High authorization, and there are no other medical device companies on that list.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- Ceribell, Inc.: Promising Growth Trajectory and Strong Market Potential Reinforce Buy Rating
- Ceribell announces FDA grants clearance for next-gen Ceribell Clarity algorithm
- Ceribell jumps after saying no impact from incremental tariffs until Q4
- Ceribell, Inc.: Strategic Resilience and Financial Health Amid Market Challenges
- Ceribell, Inc. Addresses Impact of New U.S. Tariffs